Why Is Ascendis Pharma Stock Gaining Friday?

Ascendis Pharma reported positive five-year results from its PaTH Forward trial for TransCon PTH (YORVIPATH), showing sustained efficacy and safety in treating adult hypoparathyroidism. The therapy demonstrated that 82% of patients met composite response endpoints, with 88% maintaining normal calcium levels and 96% achieving independence from active vitamin D therapy. The drug showed durable kidney benefits and a consistent safety profile with no new safety signals. ASND stock rose 3.60% to $223.37 on the news.

06/12/2026, 12:29 PM • Benzinga

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026

Ascendis Pharma announced it will present clinical trial data from its rare endocrinology programs at ENDO 2026, including two oral presentations and three posters covering hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The presentations will showcase long-term safety and efficacy data for TransCon PTH and benefits of TransCon CNP alone and combined with TransCon hGH in children with achondroplasia.

06/08/2026, 4:59 PM • GlobeNewswire

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Ascendis Pharma A/S announced plans to list its ordinary shares directly on Nasdaq effective April 20, 2026, with all outstanding American Depositary Shares (ADSs) to be exchanged on a 1:1 basis for ordinary shares. The company believes the direct listing will broaden global investment access, potentially facilitate inclusion in equity indexes, and enhance institutional ownership and trading liquidity.

04/08/2026, 12:00 PM • GlobeNewswire

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

The FDA has granted accelerated approval to YUVIWEL (navepegritide), developed by Ascendis Pharma, as the first and only once-weekly treatment for children aged 2 and older with achondroplasia. The drug provides continuous systemic exposure to CNP over the weekly dosing interval and is expected to be commercially available in early Q2 2026. The approval was based on improved annualized growth velocity data from three randomized clinical trials.

02/27/2026, 5:57 PM • GlobeNewswire

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

02/12/2026, 12:44 PM • Benzinga

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

Ascendis Pharma received notification from the FDA extending the PDUFA target action date for TransCon CNP by three months to February 28, 2026, after submitting additional information for their New Drug Application for treating children with achondroplasia.

11/25/2025, 6:15 PM • GlobeNewswire